2023-Sustainable Industrial Processing Summit
SIPS2023 Volume 1. Assis Intl. Symp/ Advanced Iron & Steel Making
| Editors: | F. Kongoli, T. Usui, R.A. Vilela, J. A. de Castro, W. F. Santos, J. Poveromo, GS. Mahobia, B. Deo |
| Publisher: | Flogen Star OUTREACH |
| Publication Year: | 2023 |
| Pages: | 441 pages |
| ISBN: | 978-1-989820-72-8 (CD) |
| ISSN: | 2291-1227 (Metals and Materials Processing in a Clean Environment Series) |
CD shopping page
DEVELOPMENT OF PRECISION THERAPY FOR HELICOBACTER PYLORI
Barry James Marshall1;1UNIVERSITY OF WESTERN AUSTRALIA, Crawley, Australia;
Type of Paper: General Plenary
Id Paper: 510
Topic: 46
Abstract:
This year marks the 40th anniversary since the ground-breaking publication on Helicobacter pylori, prompting a critical reassessment of treatment strategies within the evolving landscape of modern medicine. Historically, the global response to H. pylori infections has relied on triple therapy, involving a proton pump inhibitor (PPI) and two antibiotics. However, the escalating challenge of antibiotic resistance has emerged as a primary obstacle to achieving successful treatment outcomes. As we navigate the currents of a new era in modern medicine, characterized by the rise of precision medicine, a paradigm shift in treatment approaches becomes imperative. Precision medicine advocates for an individualized approach, emphasizing the need to precisely identify suitable antibiotics for patients before prescription. The 40th anniversary serves as a poignant reminder of the ongoing struggle against H. pylori infections and a catalyst for exploring innovative therapeutic avenues that integrate precision medicine principles. In this context, the emphasis on personalized treatment plans is crucial not only for optimizing outcomes but also for addressing the pervasive challenge of antibiotic resistance. By tailoring antibiotic regimens to the specific needs of each patient, precision medicine offers a nuanced and effective approach to combatting H. pylori. This reflective milestone encourages a forward-thinking perspective to optimize H. pylori treatment outcomes.